Subcutaneous Immunoglobulin for CIDP

• Status: Completed
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are using self administered subcutaneous IG in patients with CIDP who require IVIG. Safety, efficacy, and patient satisfaction will be examined.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Collaborator: CSL Behring
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

To qualify, a patient must have CIDP and persistence of significant symptoms (having 2 or more of the following):

• Weakness in any limb,

• Motor fatigue significant to interfere with ADL or work,

• Paresthesia of sufficient severity to require a medication,

• Sensory impairment,

• Walking impairment,

AND requires IVIG to control symptoms.

Exclusion Criteria:

1. Thrombocytopenia or other bleeding disorders,

2. Anticoagulation therapy,

3. Severe or anaphylactoid reactions to IVIG,

4. Cancer,

5. Pregnancy,

6. Breast-feeding,

7. Renal insufficiency or failure,

8. Congestive heart failure,

9. Psychiatric illness.